ESTRO 2025 - Abstract Book

S4158

RTT - Patient experience and quality of life

ESTRO 2025

Conclusion: Older patients, due to their comorbidities, already have alterations in QoL, sarcopenia being the most important factor. Cancer treatment further deteriorates QoL in a significant way, role function and fatigue, but 3 months after treatment improves QoL, significantly emotional function, fatigue, loss of appetite and maintenance of purpose.

Keywords: Quality&life, radiotherapy, elderly patient

References: AARONSON, N.K.; AHMEZDAI, S.; BERGMAN, B. y cols.: The European Organization for Research and Treatment of Cancer QLQ-C30: a Quality of Life instrument for use in intentional clinical trials. J. Natl. Cancer. Inst.; 85: 365,1993. ARRARAS, J.I.; ARIAS, F.; TEJEDOR, M. Y cols.: The EORTC QLQ-C30 (version 3.0) quality of life questionnaire. Validation study for Spain with head and neck cancer patients. Psycho-oncology; 11: 249, 2002. ARRARAS, J.I.; PRUJA, E.; TEJEDOR, M. Y cols.: El cuestionario de Calidad de Vida de la EORTC, QLQ-C30 (versión 2.0). Estudio estadístico de validación para nuestro país con pacientes con cáncer de pulmón. Rev. Oncol.; 1: 257, 1999.